Literature DB >> 20400392

Nail lichen planus: response to treatment and long term follow-up.

Bianca Maria Piraccini1, Elena Saccani, Michela Starace, Riccardo Balestri, Antonella Tosti.   

Abstract

In our twenty years' experience of dermatological visits specifically for nail diseases, we saw 105 patients with pathologically proven nail lichen planus. We prescribed treatment to 75 of these patients and we report here the results of treatment. Twenty-seven of these patients were followed-up for more than 5 years (mean follow-up was 10 years): 9 of them (9/27 = 33.3%) did not respond to treatment with steroids (intramuscular or intralesional), 18 were cured (18/27 = 66.7%), 11 relapsed (11/27 = 40.7%). This study is important for the fact that no one has previously published the results of such a long follow-up of patients with nail lichen planus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20400392     DOI: 10.1684/ejd.2010.0952

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  5 in total

Review 1.  [Diseases of the nails].

Authors:  E Haneke
Journal:  Hautarzt       Date:  2013-07       Impact factor: 0.751

Review 2.  A Compendium of Intralesional Therapies in Nail Disorders.

Authors:  Chander Grover; Shikha Bansal
Journal:  Indian Dermatol Online J       Date:  2018 Nov-Dec

3.  Promising Treatment for Twenty-Nail Dystrophy with Combination of Fractional Carbon Dioxide Laser and Topical Therapy: A Case Report.

Authors:  Kartika Ruchiatan; Lita Nuraeni; Achmad Yudha Pranata; Diah Puspitosari; Reti Hindritiani
Journal:  Int Med Case Rep J       Date:  2022-08-31

4.  Onychomadesis with Lichen Planus: An Under-Recognized Manifestation.

Authors:  Chander Grover; Suruchi Vohra
Journal:  Indian J Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.494

5.  Recommendations for treatment of nail lichen planus during the COVID-19 pandemic.

Authors:  Jose W Ricardo; Shari R Lipner
Journal:  Dermatol Ther       Date:  2020-06-04       Impact factor: 3.858

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.